Is Mitochondria DNA Variation a Biomarker for AD?

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Alzheimer's Disease (AD) is the leading cause of dementia, marked by cognitive decline.
• The exact mechanisms driving AD remain unclear, with no current early detection methods.
• Mitochondrial dysfunction is increasingly implicated in AD pathogenesis, affecting key pathologies.

Purpose of the Study:

• To review alterations in mitochondrial DNA (mtDNA) and mtDNA mutations in Alzheimer's Disease patients.
• To explore the potential of mtDNA as a biomarker for early AD diagnosis.

Main Methods:

• Literature review summarizing current research on mtDNA in AD.
• Analysis of studies investigating mtDNA variations and their impact on brain metabolism.
• Examination of the relationship between mtDNA status and AD biomarkers like amyloid-beta and tau.

Main Results:

• Mitochondrial dysfunction is a significant factor in AD.
• Variations in mtDNA affect brain energy metabolism, contributing to AD.
• Altered mitochondria functions impact both amyloid-beta and tau pathologies.

Conclusions:

• Mitochondrial DNA (mtDNA) status reflects mitochondrial health and plays a crucial role in AD.
• mtDNA and its mutations are potential biomarkers for the early diagnosis of Alzheimer's Disease.